AA
BIO icon

AlphaCentric Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

AlphaCentric Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,400
Closed -$1.63M – 235
2023
Q1 		$1.63M Hold
3,400
– – 1.12% 21
2022
Q4 		$1.43M Buy
3,400
+1,700
+100% +$686K 1.41% 16
2022
Q3 		$709K Buy
+1,700
New +$848K 0.73% 47
2021
Q4 		– Sell
-106
Closed -$79K – 227
2021
Q3 		$79K Sell
106
-65
-38% -$48.7K 0.02% 180
2021
Q2 		$110K Buy
171
+14
+9% +$8.52K 0.03% 167
2021
Q1 		$90K Sell
157
-3
-2% -$1.78K 0.03% 165
2020
Q4 		$93K Buy
160
+96
+150% +$54.7K 0.04% 143
2020
Q3 		$33K Hold
64
– – 0.02% 128
2020
Q2 		$29K Buy
+64
New +$28.2K 0.02% 106

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return